Clostridium difficile-associated diarrhea: A review

Archives of Internal Medicine

Volumn 161, Issue 4, 2001, Pages 525-533

  Mylonakis, Eleftherios ^a   Ryan, Edward T ^a   Calderwood, Stephen B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; BACITRACIN; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CISPLATIN; CLINDAMYCIN; CLOSTRIDIUM TOXIN; COTRIMOXAZOLE; DOXORUBICIN; ERYTHROMYCIN; FLUOROURACIL; MACROLIDE; METHOTREXATE; METRONIDAZOLE; QUINOLONE DERIVATIVE; RIFAMPICIN; TACROLIMUS; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC THERAPY; CLOSTRIDIUM DIFFICILE; COLITIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIFFERENTIAL DIAGNOSIS; FECES ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW;

EID: 0035952233     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.4.525     Document Type: Review

References (107)

1. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis
2. Underdescribed toxin in pseudomembranous colitis
3. Clindamycin-associated colitis due to a toxin-producing species of clostridium in hamsters
4. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
5. Severe Clostridium difficile colitis
6. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea
7. Financial burden of hospital-acquired Clostridium difficile infection
8. Community-acquired Clostridium difficile-associated diarrhea
9. Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea
10. Infectious intestinal disease in elderly people
11. Antibiotic-associated diarrhea
12. Clostridium difficile-associated diarrhoea: Epidemiological data from Western Australia
13. Nosocomial acquisition of Clostridium difficile infection
14. Nosocomial Clostridium difficile colonisation and disease
15. Epidemiology of community-acquired Clostridium difficile-associated diarrhea
16. Gastro-intestinal side effects of clindamycin and ampicillin therapy
17. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals
18. Cleaning up Clostridium difficile infection
19. Factors associated with nosocomial diarrhea and Clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital
20. Clostridium difficile infection
21. Clostridium difficile infection associated with antineoplastic chemotherapy: A review
22. Clostridium difficile colitis
23. Clostridium difficile colitis: An efficient clinical approach to diagnosis
24. Clostridium difficile-associated diarrhea in HIV-infected patients: Epidemiology and risk factors
25. Risk factors for Clostridium difficile-associated diarrhea in a cohort of hospitalized patients
26. Increased length of hospital stay due to Clostridium difficile associated diarrhoea
27. In vitro activity of new generation fiuoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates
28. Environmental control to reduce transmission of Clostridium difficile
29. Hospital disinfectants and spore formation by Clostridium difficile
30. Diminished Clostridium difficile toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor
31. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea
32. Epidemiology of antibiotic-associated colitis: Isolation of Clostridium difficile from the hospital environment
33. Acquisition of Clostridium difficile from the hospital environment
34. The role of physical proximity in nosocomial diarrhea
35. Persistence of an endemic (toxigenic) isolate of Clostridium difficile in the environment of a general medicine ward
36. Clostridium difficile diarrhea after use of tacrolimus following renal transplantation
37. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A
38. Genetic characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates by PCR
39. Pseudomembranous colitis caused by a toxin A(-) B(+) strain of Clostridium difficile
40. Definition of the single integration site of the pathogenicity locus in Clostridium difficile
41. Oligosaccharide containing sialic acid and N-acetyl-glucosamine mediate Clostridium difficile toxin B (TxB) binding and biologic effects in human colonic mucosa
42. Large clostridial cytotoxins: A family of glycosyltransferases modifying small GTP-binding proteins
43. Involvement of ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B
44. Glucosylation of Rho proteins by Clostridium difficile toxin B
45. The enterotoxin from Clostridium difficile (ToxA) monoglucosytates the Rho proteins
46. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocytes
47. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro
48. Pseudomembranous colitis
49. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease
50. Prevention of clindamycin-induced colitis in hamstere by Clostridium sordelli antitoxin
51. Protection against experimental pseudomembranes colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A
52. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters
53. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain
54. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A
55. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate
56. Antigenic cross-reactivity and functional inhibition by antibodies to Clostridium difficile toxin A, Streptococcus mutans glucan-binding protein, and a synthetic peptide
57. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters
58. Local and systemic neutralizing antibody responses induced by intranasal immunization with the nontoxic binding domain of toxin A from Clostridium difficile
59. Bovine immunoglobulin concentrate - Clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine
60. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C difficile-associated disease in a hamster model of infection
61. Serum antibody response to toxins A and B of Clostridium difficile
62. Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding
63. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection
64. Serum antibody response to Clostridium difficile toxins in patients with Clostridium difficile diarrhoea
65. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin
66. Immunogenicity of a Salmonella typhimurium aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A
67. Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease
68. The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits
69. Reactive arthritis associated with Clostridium difficile pseudomembranous colitis
70. Leukocytosis as a harbinger and surrogate marker of Clostridium difficile infection in hospitalized patients with diarrhea
71. Clostridium difficile colitis and diarrhea
72. Evaluation of four commercially available enzyme immunoassays for laboratory diagnosis of Clostridium difficile-associated diseases
73. Clostridium difficile-associated diarrhea
74. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis
75. Detection of toxinogenic Clostridium difficile in stool specimens by the polymerase chain reaction
76. Clostridium difficile infection: Pathophysiology and diagnosis
77. Diagnosis of Clostridium difficile-associated disease: Patient selection and test perfection
78. Usefulness of simultaneous detection of toxin A and glutamate dehydrogenase for the diagnosis of Clostridium difficile-associated diseases
79. Rectal sparing in antibiotic-associated pseudomembranous colitis: A prospective study
80. Clostridium difficile-associated diarrhea and colitis
81. Diagnosis and treatment of Clostridium difficile colitis
82. Ten years of prospective Clostridium difficile-associated disease surveillance and treatmerit at the Minneapolis VA Medical Center, 1982-1991
83. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis
84. Treatment of asymptomatic Clostridium difficile cartiers (fecal excretors) with vancomycin or metronidazole: A randomized, placebo-controlled study
85. Recurrent Clostridium difficile diarrhea: Characteristics of and risk factors for patients in a prospective, randomized, double-blinded trial
86. Comparison of vancomycin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea
87. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: Comparison of two dosage regimens
88. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile
89. Metronidazole resistance in Clostridium difficile
90. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea: A randomized double-blind trial
91. Antibiotic-associated colitis due to Clostridium difficile: Double-blind comparison of vancomycin with bacitracin
92. Risk factors for early recurrent Clostridium difficileassociated diarrhea
93. Recurrence of symptoms in Clostridium difficile infection: Relapse or reinfection?
94. Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea
95. Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis
96. Recurrent Clostridium difficile-associated diarrhea and colitis treated with Saccharomyces cerevisiae (baker's yeast) in combination with antibiotic therapy: A case report
97. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile diarrhea
98. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients
99. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis
100. Treatment of Clostridium difficile diarrhoea with brewer's yeast
101. Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C difficile toxins
102. Vaccination against lethal Clostridium difficile enteritis with a nontoxigenic recombinant peptide of toxin A
103. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract
104. Oral immunoglobulin A supplement in treatment of Clostddium difficile enteritis
105. Bactedotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients
106. The effect of probiotics on Clostridium difficile diarrhea
107. Clostridium difficile: Clinical disease and diagnosis